15 April 2020 in BMC Cancer
Background: The enrichment of cancer stem cell-like cells (CSCs) has been considered to be responsible for tumor progression after an initial response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung adenocarcinoma (NSCLC/ADC). CSCs with ALDH1A1bright/CD44highexpression contribute to the TKIs resistance in NSCLC/ADC cells. All-trans retinoic acid (ATRA) has been shown to be a potential targeted therapy against CSCs due to its ability to inhibit ALDH1A1 activity. We therefore investigated whether ATRA could circumvent the resistance to improve the response to gefitinib in NSCLC/ADC cells.Methods: Treatment of NSCLC/ADC A549 and H1650 cells with gefitinib enriched the gefitinib surviving cells (GSCs). The expression of ALDH1A1 and CD44 and the IC50 values for gefitinib were determined by flow cytometry (FCM) and crystal violet assay in GSCs and ATRA-treated GSCs, respectively. Using DEAB as the positive control, direct inhibitory effect of ATRA on ALDH1A1 activity was determined by ALDEFLUOR assay,Results: GSCs showed higher expression of ALDH1A1 and CD44 and IC50 values for gefitinib than their respective parental cells, suggesting that gefitinib can lead to propagation of CSC-enriched gefitinib-resistant cells. Treatment with ATRA was found to significantly reduce the increased expression of ALDH1A1 and CD44 and the IC50 values for gefitinib in A549GSC and H1650GSC cells, and ATRA could directly inhibit active ALDH1A1 as compared to DEAB.Conclusion: Our findings suggest that combination treatment with ATRA prevents gefitinib-induced enrichment of ALDH1A1bright/CD44highCSCs and enhances gefitinib-induced growth inhibition of NSCLC/ADC cells.
1 January 2017 in Saudi Medical Journal
Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trials
24 April 2026 in Frontiers in Immunology
Epstein-Barr virus (EBV) is associated with a wide spectrum of lymphoid and epithelial malignancies. This review provides a comprehensive pan-tumor perspective on the convergent oncogenic mechanisms, immune microenvironment characteristics, and shared therapeutic vulnerabilities across EBV-related cancers. We systematically summarize EBV infection and latency patterns, highlighting key shared signaling networks (e.g., NF-κB, PI3K/AKT) alongside nuanced immune evasion strategies, such as HLA modulation and steric immune blockade. By bridging these molecular insights with clinical translation, we evaluate emerging therapeutic paradigms, including immune checkpoint inhibitors, EBV-specific T-cell therapies, neutralizing antibodies, and mRNA vaccines. Ultimately, this synthesis underscores the potential of exploiting shared viral vulnerabilities to develop pan-tumor targeted therapies, offering a strategic roadmap for future clinical development.